APA (7th ed.) Citation

AD, N., DDSP, C., T, M., WB, B., J, M., & MM, F. (2026). Efficacy and safety analysis of the use of ibrutinib associated with rituximab for the first-line treatment of patients with chronic lymphocytic leukaemia. Hematology, transfusion and cell therapy, 48(1), 106234. https://doi.org/10.1016/j.htct.2025.106234

Chicago Style (17th ed.) Citation

AD, Nascimento, Curado DDSP, Montezuma T, Barbosa WB, Machado-Rugolo J, and Fachi MM. "Efficacy and Safety Analysis of the Use of Ibrutinib Associated with Rituximab for the First-line Treatment of Patients with Chronic Lymphocytic Leukaemia." Hematology, Transfusion and Cell Therapy 48, no. 1 (2026): 106234. https://doi.org/10.1016/j.htct.2025.106234.

MLA (9th ed.) Citation

AD, Nascimento, et al. "Efficacy and Safety Analysis of the Use of Ibrutinib Associated with Rituximab for the First-line Treatment of Patients with Chronic Lymphocytic Leukaemia." Hematology, Transfusion and Cell Therapy, vol. 48, no. 1, 2026, p. 106234, https://doi.org/10.1016/j.htct.2025.106234.